
|Videos|July 24, 2021
Pipeline: Presbyopia, night vision disturbance up next for Vyluma
Advertisement
Presbyopia and night vision disturbance will follow myopia as a clinical focus for Vyluma. Navneet Puri, PhD, the company’s founder, chairman, and CEO, shares what is next.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Ortho-k: More than meets the eye to control myopia progression
2
Drs Kaleb Abbott, Andrew Pucker suggest changing "artificial tear" terminology
3
Crafting your own eyewear brand: Streamlining the private label process
4
ONL Therapeutics reports positive phase 1b data for xelafaslatide in GA
5












































.png)


